cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Budi Santoso
Contact Email
juxta@journal.unair.ac.id
Phone
-
Journal Mail Official
juxta@journal.unair.ac.id
Editorial Address
-
Location
Kota surabaya,
Jawa timur
INDONESIA
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Published by Universitas Airlangga
ISSN : 19073623     EISSN : 26849453     DOI : -
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health
Juxta (Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga) is a scientific peer-reviewed medical doctor which relevant to a medical doctor and other health-related professions by the Faculty of Medicine Universitas Airlangga, Indonesia. Juxta provides a forum for original article to the editor and it will be published Two-times a year. Studies that focus on evaluating and understanding the complex medical importance are welcomed in Juxta.
Arjuna Subject : -
Articles 191 Documents
 9   10   11   12   13 
Front Matter Vol 11 No 1, 2020 Front Matter
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 11 No. 1 (2020): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Front Matter Vol 11 No 2, 2020 Front Matter
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 11 No. 2 (2020): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Front Matter Vol 12 No 1, 2021 Front Matter
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 12 No. 1 (2021): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Front Matter Vol 12 No 2, 2021 Front Matter
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 12 No. 2 (2021): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Front Matter Vol 13 No 1, 2022 Front Matter
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 13 No. 1 (2022): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Back Matter Vol 14 No 1, 2023 Back Matter
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 14 No. 1 (2023): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Front Matter Vol 14 No 1, 2023 Front Matter
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 14 No. 1 (2023): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Front Matter Vol 13 No 2, 2022 Front Matter
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 13 No. 2 (2022): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The Effectiveness of Meloxicam Adjuvant Therapy to Improve Cognitive Function of Schizophrenic Patients Islamy, Nabila Nur Bilqis; Nugroho, I Gusti Bagus Indro; Herdaetha, Adriesti
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 14 No. 2 (2023): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/juxta.V14I22023.52-56

Abstract

Highlights:1. Schizophrenic patients have cognitive dysfunction.2. Meloxicam, as an adjuvant therapy, can improve cognitive function in schizophrenic patients. AbstractIntroduction: Schizophrenia is a chronic psychotic disorder triggered by genetic and environmental factors such as an inflammatory response. The inflammatory response in schizophrenic patients increases with cognitive decline. Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) group with Cyclo-oxygenase (COX-2) inhibitory activity and can suppress the production of inflammatory cytokines. This study aimed to determine the efficacy of Meloxicam as an adjuvant therapy to improve cognitive function in schizophrenic patients.Methods: This was a quasi-experimental study using a single-blind, pretest–post-test design. The sample size in this study was 34 subjects who had met the inclusion and exclusion criteria. All samples were divided into two groups, namely the treatment group, with as many as 17 subjects receiving additional therapy with Meloxicam 15 mg/day for 4 weeks, and the control group, with 17 subjects. The score of the Schizophrenia Cognition Rating Scale (ScoRS) was assessed before and after therapy. Data analysis used SPSS 25.0. In both groups, the SCoRS score was different.Results: In the treatment group, there was a decrease in the SCoRS score that was greater than in the control group. There was a statistically significant difference with p = 0.002 in decreasing SCoRS scores.Conclusion: In the treatment group, there was a decrease in the SCoRS score that was greater than in the control group. There was a statistically significant difference with p = 0.002 in decreasing SCoRS scores.
The Differences in Adjuvant Therapy Effectiveness Meloxicam and N-Acetylcysteine against Negative Symptoms of Schizophrenia Murda, Banu Kadgada Kalingga; Nugroho, I Gusti Bagus Indro; Herdaetha, Adriesti
JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 14 No. 2 (2023): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/juxta.V14I22023.63-69

Abstract

Highlights:1. Schizophrenic patients can have negative symptoms.2. Adjuvant therapy is needed to assist antipsychotics in reducing the negative symptoms of schizophrenic patients. AbstractIntroduction: Meloxicam and N-Acetylcysteine are examples of drugs with anti-inflammatory effects that have been widely studied, and are considered to reduce negative symptoms of schizophrenia. Both of these drugs are also widely available in Indonesia and can be obtained at an affordable price. This study aimed to analyze the differences in the effectiveness of adjuvant therapy meloxicam and N-Acetylcysteine on negative symptoms of schizophrenic patients. Methods: This was a quasi-experimental study using a single-blind, pretest–post-test design. Determination of the subject used a purposive sampling technique according to the inclusion criteria. This study examined 34 samples and divided them into two groups. In group A, 17 subjects received adjuvant meloxicam therapy of 15 mg/day for 4 weeks; in group B, 17 subjects received adjuvant therapy of N-Acetylcysteine 400 mg/day for 4 weeks. Score assessment was performed using the positive scale, negative scale, and general psychopathology scale (PANSS) negative subscale pre- and post-therapy, then compared the effectiveness. Data analysis used SPSS 25.0.Results: The mean score of the PANSS post-test subscale was negative in the meloxicam adjuvant therapy group 15.58, while for the N-Acetylcysteine adjuvant therapy group was 17.64 with a p-value of 0.009. The mean decrease in the negative subscale PANSS score in the meloxicam adjuvant therapy group was 11.00, while the N-Acetylcysteine adjuvant therapy group was 19.70 with a p-value of 0.000.Conclusion: There was no difference in the effectiveness of adjuvant therapy meloxicam and N-Acetylcysteine in improving negative symptoms of schizophrenic patients.

Page 11 of 20 | Total Record : 191

 9   10   11   12   13 

Filter by Year

2019 2026


Reset
Filter By Issues
All Issue Vol. 17 No. 1 (2026): JANUARY 2026 (IN-PROGRESS ISSUE) Vol. 16 No. 2 (2025): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 16 No. 1 (2025): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 15 No. 2 (2024): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 15 No. 1 (2024): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 14 No. 2 (2023): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 14 No. 1 (2023): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 13 No. 2 (2022): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 13 No. 1 (2022): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 12 No. 2 (2021): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 12 No. 1 (2021): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 11 No. 2 (2020): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 11 No. 1 (2020): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 10 No. 2 (2019): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga Vol. 10 No. 1 (2019): Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga More Issue